{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:40:46Z","timestamp":1789656046178,"version":"4.0.1"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Clinical Specialty Project for Hepatobiliary Surgery","award":["Qinghai Health Commission - 125"],"award-info":[{"award-number":["Qinghai Health Commission - 125"]}]},{"name":"2022 Science and Technology Plan of Qinghai Science and Technology Department"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Pancreatic resection is a critical treatment for pancreatic cancer and other pancreatic diseases. Somatostatin analogs are commonly used to prevent complications following pancreatic resection, but their efficacy and safety remain debated.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Following PRISMA guidelines, a systematic search was conducted across multiple databases, including PubMed, EMBASE, Scopus, Cochrane Library, Ovid, ClinicalTrials.gov, Web of Science, CNKI, and WanFang Data. The search focused on studies comparing the use of somatostatin analogs after pancreatic surgery. Key outcomes included postoperative pancreatic fistula (POPF), clinically relevant POPF (CR-POPF), mortality, and morbidity. Statistical analysis was performed using a consistency model, calculating relative risk ratios (RR) with 95% confidence intervals (CI), and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool was used to assess the quality of evidence.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>In the absence of stratification based on the surgical procedure, For POPF prevention, pasireotide showed a relative risk (RR) of 0.46 (95% CI: 0.23, 0.87, Low) compared to placebo, and octreotide had an RR of 0.76 (95% CI: 0.66, 0.88, Moderate). Somatostatin and vapreotide showed no significant differences. In preventing CR-POPF, pasireotide had an RR of 0.46 (95% CI: 0.23, 0.86, Low), somatostatin had an RR of 0.60 (95% CI: 0.36, 0.99, Moderate), and octreotide had an RR of 0.61 (95% CI: 0.39, 0.94, Moderate). Regarding postoperative mortality, vapreotide showed an RR of 0 (95% CI: 0.00, 0.29, Low), while octreotide, somatostatin and pasireotide did not demonstrate significant effects. For reducing morbidity, octreotide had an RR of 0.74 (95% CI: 0.66, 0.82, Moderate), somatostatin had an RR of 0.76 (95% CI: 0.66, 0.87, Moderate), vapreotide and pasireotide showed no significant effect.In Pancreaticoduodenectomy subgroup, somatostatin showed an RR of 0.22(95% CI: 0.03, 0.84, Moderate) for preventing CR-POPF.For all the other outcomes, neither somatostatin nor octreotide proved effective.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>While robust evidence confirms the efficacy of octreotide in preventing POPF, a critical concern regarding its inconsistent efficacy within the PD subgroup persists. This variability indicates that the overall clinical benefit of octreotide may be predominantly attributable to its utility in non-PD pancreatic resections.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0331909","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:32:02Z","timestamp":1758310322000},"page":"e0331909","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["The influence of somatostatin analogues on the incidence of pancreatic fistulas and postoperative morbidity in patients undergoing pancreatic resection: A Bayesian network meta-analysis"],"prefix":"10.1371","volume":"20","author":[{"given":"Zonghao","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5313-5732","authenticated-orcid":true,"given":"Haining","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"12","key":"pone.0331909.ref001","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1177\/00031348231175500","article-title":"Completion Pancreatectomy as a Treatment Option for Complications Following Pancreatoduodenectomy","volume":"89","author":"K Bramis","year":"2023","journal-title":"Am Surg"},{"issue":"3","key":"pone.0331909.ref002","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/surgeries5030071","article-title":"Prevention of Postoperative Pancreatic Fistula: Systematic Review and Meta-Analysis","volume":"5","author":"L Alzelfawi","year":"2024","journal-title":"Surgeries"},{"issue":"5","key":"pone.0331909.ref003","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00595-016-1426-1","article-title":"Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review","volume":"47","author":"Y Watanabe","year":"2017","journal-title":"Surg Today"},{"issue":"11","key":"pone.0331909.ref004","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.hpb.2022.07.011","article-title":"A phase II trial of lanreotide for the prevention of postoperative pancreatic fistula","volume":"24","author":"VG Pillarisetty","year":"2022","journal-title":"HPB (Oxford)"},{"key":"pone.0331909.ref005","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpb.2022.05.820","article-title":"Lanreotide for the Prevention of Postoperative Pancreatic Fistula: Phase Ii Clinical Trial Results","volume":"24","author":"A Abbasi","year":"2022","journal-title":"HPB"},{"issue":"11","key":"pone.0331909.ref006","first-page":"61","article-title":"Prevention of pancreatic fistula after pancreatoduodenectomy","author":"AG Kriger","year":"2020","journal-title":"Khirurgiia (Mosk)"},{"issue":"4","key":"pone.0331909.ref007","article-title":"Somatostatin analogues for pancreatic surgery","volume":"2013","author":"KS Gurusamy","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0331909.ref008","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"10","key":"pone.0331909.ref009","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"M Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0331909.ref010","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"JPT Higgins","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"pone.0331909.ref011","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00423-019-01761-6","article-title":"Evidence-based recommendations for blinding in surgical trials","volume":"404","author":"P Probst","year":"2019","journal-title":"Langenbecks Arch Surg"},{"issue":"1","key":"pone.0331909.ref012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"G van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"issue":"3","key":"pone.0331909.ref013","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"L Lin","year":"2018","journal-title":"Biometrics"},{"issue":"1","key":"pone.0331909.ref014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9610(92)90264-R","article-title":"Role of octreotide in the prevention of postoperative complications following pancreatic resection","volume":"163","author":"M B\u00fcchler","year":"1992","journal-title":"Am J Surg"},{"issue":"2","key":"pone.0331909.ref015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/bjs.1800810237","article-title":"Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian Study Group","volume":"81","author":"P Pederzoli","year":"1994","journal-title":"Br J Surg"},{"issue":"9","key":"pone.0331909.ref016","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/bjs.1800820938","article-title":"Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis","volume":"82","author":"H Friess","year":"1995","journal-title":"Br J Surg"},{"issue":"1","key":"pone.0331909.ref017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0039-6060(05)80225-9","article-title":"Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial","volume":"117","author":"M Montorsi","year":"1995","journal-title":"Surgery"},{"issue":"5","key":"pone.0331909.ref018","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00000658-199711000-00008","article-title":"Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease","volume":"226","author":"AM Lowy","year":"1997","journal-title":"Ann Surg"},{"issue":"1","key":"pone.0331909.ref019","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0002-9610(97)00236-5","article-title":"A prospective randomized clinical trial of perioperative treatment with octreotide in pancreas transplantation","volume":"175","author":"E Benedetti","year":"1998","journal-title":"Am J Surg"},{"issue":"3","key":"pone.0331909.ref020","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00000658-200009000-00014","article-title":"Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial","volume":"232","author":"CJ Yeo","year":"2000","journal-title":"Ann Surg"},{"issue":"3","key":"pone.0331909.ref021","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archsurg.139.3.288","article-title":"Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial","volume":"139","author":"B Suc","year":"2004","journal-title":"Arch Surg"},{"issue":"10","key":"pone.0331909.ref022","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00268-005-7546-1","article-title":"Prospectively randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreatico-jejunostomy","volume":"29","author":"UJ Hesse","year":"2005","journal-title":"World J Surg"},{"issue":"8","key":"pone.0331909.ref023","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ejso.2008.01.014","article-title":"Prophylactic octreotide and delayed gastric emptying after pancreaticoduodenectomy: results of a prospective randomized double-blinded placebo-controlled trial","volume":"34","author":"O Kollmar","year":"2008","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"pone.0331909.ref024","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1477-2574.2012.00608.x","article-title":"Prospective randomized trial of the effect of octreotide on pancreatic juice output after pancreaticoduodenectomy in relation to histological diagnosis, duct size and leakage","volume":"15","author":"L Fern\u00e1ndez-Cruz","year":"2013","journal-title":"HPB (Oxford)"},{"issue":"11","key":"pone.0331909.ref025","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1007\/s11605-015-2925-x","article-title":"Octreotide Does Not Prevent Pancreatic Fistula Following Pancreatoduodenectomy in Patients with Soft Pancreas and Non-dilated Duct: A Prospective Randomized Controlled Trial","volume":"19","author":"P Kurumboor","year":"2015","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"pone.0331909.ref026","first-page":"21","article-title":"Impact of octreotide on pancreatic fistula after pancreaticoduodenectomy: a prospective study","volume":"54","author":"R Kong","year":"2016","journal-title":"Zhonghua Wai Ke Za Zhi"},{"issue":"1","key":"pone.0331909.ref027","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.hbpd.2018.01.015","article-title":"Efficacy of octreotide in the prevention of complications after pancreaticoduodenectomy in patients with soft pancreas and non-dilated pancreatic duct: A prospective randomized trial","volume":"17","author":"A El Nakeeb","year":"2018","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"2","key":"pone.0331909.ref028","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.asjsur.2018.08.006","article-title":"Randomized controlled study of the effect of octreotide on pancreatic exocrine secretion and pancreatic fistula after pancreatoduodenectomy","volume":"42","author":"DD You","year":"2019","journal-title":"Asian J Surg"},{"issue":"2","key":"pone.0331909.ref029","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/SLA.0000000000006313","article-title":"Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study","volume":"280","author":"S Gaujoux","year":"2024","journal-title":"Ann Surg"},{"key":"pone.0331909.ref030","article-title":"Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy","author":"C Gouillat","year":"2001","journal-title":"Wiley Online Library"},{"key":"pone.0331909.ref031","first-page":"179","article-title":"The role of somatostatin in 67 consecutive pancreatectomies: a randomized clinical trial","volume":"3","author":"A Katsourakis","year":"2010","journal-title":"Clin Exp Gastroenterol"},{"issue":"10","key":"pone.0331909.ref032","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1007\/s00535-021-01818-8","article-title":"A randomised, multicentre trial of somatostatin to prevent clinically relevant postoperative pancreatic fistula in intermediate-risk patients after pancreaticoduodenectomy","volume":"56","author":"Z Cao","year":"2021","journal-title":"J Gastroenterol"},{"issue":"10","key":"pone.0331909.ref033","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00268-005-7943-5","article-title":"Effects of somatostatin prophylaxis after pylorus-preserving pancreaticoduodenectomy: increased delayed gastric emptying and reduced plasma motilin","volume":"29","author":"Y-S Shan","year":"2005","journal-title":"World J Surg"},{"issue":"6","key":"pone.0331909.ref034","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00268-003-6693-5","article-title":"Role of somatostatin in the prevention of pancreatic stump-related morbidity following elective pancreaticoduodenectomy in high-risk patients and elimination of surgeon-related factors: prospective, randomized, controlled trial","volume":"27","author":"Y-S Shan","year":"2003","journal-title":"World J Surg"},{"issue":"1","key":"pone.0331909.ref035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MPA.0b013e3182557c24","article-title":"Does prophylactic administration of somatostatin decrease the rates of complications after pancreatic resection?: A clinical and electron microscopy study","volume":"42","author":"A Katsourakis","year":"2013","journal-title":"Pancreas"},{"issue":"21","key":"pone.0331909.ref036","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa1313688","article-title":"Pasireotide for postoperative pancreatic fistula","volume":"370","author":"PJ Allen","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0331909.ref037","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1072-7515(03)00104-2","article-title":"The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial","volume":"196","author":"MG Sarr","year":"2003","journal-title":"J Am Coll Surg"},{"issue":"12","key":"pone.0331909.ref038","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1177\/0003134820947371","article-title":"Meta-Analysis on the Effect of Pasireotide for Prevention of Postoperative Pancreatic Fistula","volume":"86","author":"EC Dalton","year":"2020","journal-title":"Am Surg"},{"issue":"8","key":"pone.0331909.ref039","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.pan.2020.10.043","article-title":"Do somatostatin-analogues have the same impact on postoperative morbidity and pancreatic fistula in patients after pancreaticoduodenectomy and distal pancreatectomy? - A systematic review with meta-analysis of randomized-controlled trials","volume":"20","author":"S Schorn","year":"2020","journal-title":"Pancreatology"},{"issue":"2","key":"pone.0331909.ref040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1472-8206.1995.tb00269.x","article-title":"Molecular pharmacology of somatostatin receptors","volume":"9","author":"C Viollet","year":"1995","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"pone.0331909.ref041","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41422-022-00679-x","article-title":"Structural insights into ligand recognition and selectivity of somatostatin receptors","volume":"32","author":"W Zhao","year":"2022","journal-title":"Cell Res"},{"issue":"2","key":"pone.0331909.ref042","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1677\/jme.0.0170089","article-title":"Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors","volume":"17","author":"T Florio","year":"1996","journal-title":"J Mol Endocrinol"},{"issue":"5","key":"pone.0331909.ref043","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2174\/1389450116666141205163548","article-title":"Somatostatin and its Analogs","volume":"17","author":"L Sun","year":"2016","journal-title":"Curr Drug Targets"},{"issue":"5","key":"pone.0331909.ref044","first-page":"658","article-title":"Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion","volume":"38","author":"PE Battershill","year":"1989","journal-title":"Drugs"},{"issue":"4","key":"pone.0331909.ref045","first-page":"255","article-title":"Octreotide, a new somatostatin analogue","volume":"8","author":"MD Katz","year":"1989","journal-title":"Clin Pharm"},{"issue":"5","key":"pone.0331909.ref046","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000350468","article-title":"Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor","volume":"20","author":"S Spitsin","year":"2013","journal-title":"Neuroimmunomodulation"},{"issue":"3","key":"pone.0331909.ref047","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11154-022-09710-3","article-title":"Pasireotide\u2014a novel somatostatin receptor ligand after 20 years of use","volume":"23","author":"M Bolanowski","year":"2022","journal-title":"Reviews in Endocrine & Metabolic Disorders"},{"issue":"1","key":"pone.0331909.ref048","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11102-018-0926-y","article-title":"Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells","volume":"22","author":"F Gatto","year":"2019","journal-title":"Pituitary"},{"issue":"10","key":"pone.0331909.ref049","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2174\/1389200219666180328113801","article-title":"Pasireotide - Mechanism of Action and Clinical Applications","volume":"19","author":"N Sawicka-Gutaj","year":"2018","journal-title":"Curr Drug Metab"},{"issue":"8","key":"pone.0331909.ref050","first-page":"408","article-title":"Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors","volume":"10","author":"R Ayyagari","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"pone.0331909.ref051","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14737167.2018.1513330","article-title":"Cost-effectiveness of somatostatin analogues in the treatment of acromegaly","volume":"19","author":"E Orlewska","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"pone.0331909.ref052","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462324002204","article-title":"PP49 Prescribing Trends And Economic Impact Of Somatostatin Analogues In Acromegaly: A Threat To Brazil\u2019s Public Health System Sustainability","volume":"40","author":"LB Porto Dantas","year":"2024","journal-title":"Int J Technol Assess Health Care"},{"issue":"5","key":"pone.0331909.ref053","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3390\/ijms21051682","article-title":"Somatostatin Analogs in Clinical Practice: a Review","volume":"21","author":"M Gomes-Porras","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"pone.0331909.ref054","first-page":"658","article-title":"Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion","volume":"38","author":"PE Battershill","year":"1989","journal-title":"Drugs"},{"key":"pone.0331909.ref055","doi-asserted-by":"crossref","first-page":"106707","DOI":"10.1016\/j.ijsu.2022.106707","article-title":"Does pancreatic duct stent placement lead to decreased postoperative pancreatic fistula rates after pancreaticoduodenectomy? A meta-analysis","volume":"103","author":"C Guo","year":"2022","journal-title":"Int J Surg"},{"issue":"4","key":"pone.0331909.ref056","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/SLA.0000000000006564","article-title":"Comparative Assessment of Outcomes: Abdominal Drain Versus No Abdominal Drain After Left Pancreatectomy-A Systematic Review and Meta-analysis","volume":"281","author":"M Fatima","year":"2025","journal-title":"Ann Surg"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:51:58Z","timestamp":1758318718000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331909"}},"subtitle":[],"editor":[{"given":"Kenji","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0331909","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}